PURCHASE, N. Y. , July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi, has been invited to participate in a fireside discussion at the B.

globenewswire.com - 2026-07-13 07:30:00

PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi, has been invited to participate in a fireside discussion at the B. Riley Mind, Muscle & Vision Summit on July 16, 2026. During the discussion with analyst, William Wood, Ph.D., Ms. Ricciardi will review the status of the Company's ongoing START study as well as the planned initiation of a Phase 3 registrational study of zervimesine (CT1812) in dementia with Lewy bodies (DLB) psychosis.

globenewswire.com - 2026-07-13 07:30:00

Cognition Therapeutics is currently prioritizing zervimesine for DLB psychosis. This is after the FDA's feedback gave their planned pivotal program a clearer path. Basically, DLB psychosis has no approved therapy, and zervimesine is a promising oral once-daily drug that already has interesting Phase 2 data. CGTX's SHIMMER trial was a good start, but their next trial must confirm longer-lasting hallucination and delusion benefits.

seekingalpha.com - 2026-06-26 10:07:20

- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis -

globenewswire.com - 2026-06-24 07:30:00

PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468.

globenewswire.com - 2026-06-16 07:30:00

PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi intends to present at two financial conferences in June, where she will provide updates on the Company's plans for a registration program in DLB psychosis. Live and archived webcasts of Ms. Ricciardi's presentations will be available on the Investor Relations section of Cognition's website.

globenewswire.com - 2026-06-01 07:30:00

- Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), conducted a planned meeting with the U.S. Food and Drug Administration (FDA) on May 20, 2026.

globenewswire.com - 2026-05-21 07:30:00

PURCHASE, N.Y., May 14, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a second philanthropic donation has been received from a participant in the ongoing expanded access program (EAP) for people with dementia with Lewy bodies (DLB). The ongoing EAP has been extended to provide two years of treatment for participants, thanks to a generous new donation from Mr. Jeffrey Pechter, founding partner of Mindful Capital in Delray Beach, FL.

globenewswire.com - 2026-05-14 07:30:00

Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to inform registrational plans for zervimesine in DLB psychosis PURCHASE, N.Y., May 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

globenewswire.com - 2026-05-07 16:15:00

Cognition Therapeutics, Inc. (NASDAQ: CGTX - Get Free Report) CEO Lisa Ricciardi bought 9,175 shares of the stock in a transaction that occurred on Thursday, April 16th. The stock was bought at an average cost of $1.10 per share, for a total transaction of $10,092.50. Following the completion of the purchase, the chief executive officer directly

defenseworld.net - 2026-04-21 04:57:01

Cognition Therapeutics, Inc. (NASDAQ: CGTX - Get Free Report) CFO John Brendan Doyle acquired 10,000 shares of the firm's stock in a transaction that occurred on Thursday, April 16th. The shares were bought at an average price of $1.13 per share, with a total value of $11,300.00. Following the completion of the purchase, the chief financial

defenseworld.net - 2026-04-21 04:56:48

Cognition Therapeutics (NASDAQ: CGTX) executives told investors at the Needham conference that the company is preparing to advance its once-daily oral candidate zervimesine into late-stage development, with an initial focus on psychosis symptoms in dementia with Lewy bodies (DLB) while continuing to run a large National Institute on Aging (NIA)-funded Alzheimer's disease study. Pipeline focus shifts

defenseworld.net - 2026-04-15 03:35:08